Rosen Law Firm Notifies Erasca Investors of August 10 Lead Plaintiff Deadline
Rosen Law Firm has announced a lead plaintiff deadline of August 10, 2026, for investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026.
NEW YORK, July 27, 2026 – Rosen Law Firm, a global investor rights law firm, has alerted purchasers of common stock in Erasca, Inc. (NASDAQ: ERAS) to an important August 10, 2026 deadline. The deadline applies to investors who acquired Erasca stock between January 14, 2025, and April 26, 2026, inclusive, and wish to serve as lead plaintiff in a securities fraud class action.
The lawsuit alleges that Erasca, Inc., its Chief Executive Officer, and Chief Financial Officer violated federal securities laws. According to the complaint, the company made materially false and misleading statements regarding its lead oncology drug candidate, ERAS-0015. The complaint claims Erasca repeatedly promoted ERAS-0015 as potentially "best-in-class" and highlighted purportedly superior preclinical results compared to Revolution Medicines' RMC-6236.
These comparisons, the lawsuit contends, were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. Investors allegedly suffered damages when the true details of these issues became public knowledge.
Rosen Law Firm is offering to represent affected investors on a contingency fee basis, meaning clients pay no out-of-pocket costs. The firm encourages potential lead plaintiffs to seek experienced counsel and reminds investors that they are not represented by counsel unless they retain a firm. Investors can elect to remain an absent class member and do nothing at this point.